Florence Brown, MD
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1578597316
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $99 of the $124 with a category attached, or 79.8%. 3 manufacturers reported payments, led by Abbott at 44.9% of the total. Reporting peaked in 2023 at $76 and has fallen 69.3% since, to $23 in 2024. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MA, where the typical reported total is $583.
Across 4 payments — averaging $30.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$56
- Dexcom, Inc.$43
- Lilly USA, LLC$25
Across 13 payments — averaging $42,959 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$558K
What the payments were for
- Food & beverage$9980%
- Education$2520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 2 | $56 |
| Dexcom, Inc. | 1 | $43 |
| Lilly USA, LLC | 1 | $25 |
How this compares
$124 in reported general payments places this provider in the 25th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $92,872 |
| TrulicityDulaglutide | 13 | $29,994 |
| HumalogInsulin Lispro | 39 | $13,720 |
| JardianceEmpagliflozin | 17 | $13,365 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $8,033 |
| NovologInsulin Aspart | 24 | $6,978 |
| LantusInsulin Glargine,hum.Rec.Anlog | 35 | $6,661 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 26 | $3,853 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,575 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $2,311 |
| Atorvastatin Calcium | 70 | $1,165 |
| Insulin SyringeSyringe-Needle,insulin,0.5 Ml | 17 | $1,164 |
| Rosuvastatin Calcium | 22 | $735 |
| Pravastatin Sodium | 16 | $527 |
| Metformin Hcl | 41 | $411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Humalog | $25 | $43,71452 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Boston
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Augusto Caballero-RoblesBoston$150K
- Osama HamdyBoston$117K
- Barbara KahnBoston$105K
- Naomi FisherBoston$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.